Can Immunome Inc’s (IMNM) drop of -1.01% in a week be considered a lucky break?

On Monday, Immunome Inc (NASDAQ: IMNM) was -5.25% drop from the session before settling in for the closing price of $9.34. A 52-week range for IMNM has been $8.55 – $28.19.

When this article was written, the company’s average yearly earnings per share was at 17.82%. With a float of $69.67 million, this company’s outstanding shares have now reached $84.67 million.

In an organization with 55 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 88.22%, operating margin of -3134.4%, and the pretax margin is -3014.59%.

Immunome Inc (IMNM) Insider and Institutional Ownership

Also, it is sometimes useful to examine the sentiment of large-scale investors toward Immunome Inc stocks. The insider ownership of Immunome Inc is 17.73%, while institutional ownership is 63.09%. The most recent insider transaction that took place on Jan 31 ’25, was worth 1,162,500. In this transaction President and CEO of this company bought 150,000 shares at a rate of $7.75, taking the stock ownership to the 669,636 shares. Before that another transaction happened on Nov 21 ’24, when Company’s President and CEO bought 66,057 for $9.54, making the entire transaction worth $630,263. This insider now owns 485,693 shares in total.

Immunome Inc (IMNM) Latest Financial update

Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.69 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around 17.82% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 16.01% during the next five years compared to -48.48% drop over the previous five years of trading.

Immunome Inc (NASDAQ: IMNM) Trading Performance Indicators

You can see what Immunome Inc (IMNM) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 6.17. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 73.98.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -8.12, a number that is poised to hit -0.67 in the next quarter and is forecasted to reach -3.09 in one year’s time.

Technical Analysis of Immunome Inc (IMNM)

Let’s dig in a bit further. During the last 5-days, its volume was 0.68 million. That was inferior than the volume of 0.93 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 42.03%. Additionally, its Average True Range was 0.73.

During the past 100 days, Immunome Inc’s (IMNM) raw stochastic average was set at 5.14%, which indicates a significant decrease from 17.35% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 60.32% in the past 14 days, which was lower than the 74.30% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $10.15, while its 200-day Moving Average is $12.58. However, in the short run, Immunome Inc’s stock first resistance to watch stands at $9.40. Second resistance stands at $9.96. The third major resistance level sits at $10.40. If the price goes on to break the first support level at $8.40, it is likely to go to the next support level at $7.96. The third support level lies at $7.40 if the price breaches the second support level.

Immunome Inc (NASDAQ: IMNM) Key Stats

There are 79,777K outstanding shares of the company, which has a market capitalization of 749.37 million. As of now, sales total 14,020 K while income totals -106,810 K. Its latest quarter income was 2,910 K while its last quarter net income were -47,100 K.